Description: Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People's Republic of China. Its core product is EAL, a multi-target cellular immunotherapy product that is in Phase II clinical trials for the prevention of postsurgical recurrence of liver cancer. The company is also conducting pre-clinical and clinical trial studies for EAL to treat lung cancer, glioma, gastric cancer, and colorectal cancer. In addition, it develops 6B11-OCIK injection that is in Phase I clinical trial for ovarian cancer; CAR-T-19 injection product for B-cell acute lymphoblastic leukaemia; and TCR-T cell series products to treat solid tumors. The company was founded in 2006 and is headquartered in Beijing, the People's Republic of China.
Home Page: www.eaal.net
Guosheng Technology Park
Beijing,
China
Phone:
Officers
| Name | Title |
|---|---|
| Mr. Zheng Tan | Exec. Chairman |
| Dr. Wang Yu | CEO, Co-Chief Technology Officer & Exec. Director |
| Mr. Ning Yang | CFO & Company Sec. |
| Dr. Yu Zhang | Chief Scientist |
| Mr. Hyun Chul Jung | Chief Strategy Officer & Exec. Director |
| Dr. Hyun-Soo Lee | Co-Chief Technology Officer |
| Mr. Jian Zhang | Sr. VP |
Exchange: HK
Country: HK : Hong Kong
Currency: Hong Kong Dollar (HK$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.4069 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 268 |